30 results on '"Joel Moss"'
Search Results
2. Pulmonary Langerhans Cell Histiocytosis and Lymphangioleiomyomatosis Have Circulating Cells With Loss of Heterozygosity of the TSC2 Gene
- Author
-
Davide Elia, Olga Torre, Chiara Vasco, Jens Geginat, Sergio Abrignani, Elisabetta Bulgheroni, Elena Carelli, Roberto Cassandro, Gustavo Pacheco-Rodriguez, Wendy K. Steagall, Joel Moss, and Sergio Harari
- Subjects
Lung Diseases ,Pulmonary and Respiratory Medicine ,Histiocytosis, Langerhans-Cell ,Tumor Suppressor Proteins ,Tuberous Sclerosis Complex 2 Protein ,Humans ,Loss of Heterozygosity ,Lymphangioleiomyomatosis ,Cardiology and Cardiovascular Medicine ,Critical Care and Intensive Care Medicine - Abstract
Lymphangioleiomyomatosis (LAM) and pulmonary Langerhans cell histiocytosis (PLCH) are cystic lung diseases in which a neoplastic cell is thought to be responsible for disease pathogenesis. The neoplastic LAM cell has mutations in the TSC genes, TSC1 or TSC2, whereas the neoplastic PLCH cell may have mutations in several genes (eg, BRAF, NRAS, MAP2K1). These mutations are not specific for PLCH and have been described in multiple cancers. TSC1 or TSC2 mutations and loss of heterozygosity (LOH) have also been described in cancers.Is TSC2 LOH specific to LAM or is it also found in PLCH?We recruited patients with LAM (n = 53) and healthy volunteers (n = 22) and compared the presence of cells with TSC2 LOH with patients with PLCH (n = 12). Blood and urine samples were collected for analysis. Fluorescence-activated cell sorting (FACS) was used to identify subpopulations of cells from blood and urine samples. We isolated CD45-CD235a-, CD45-CD235a+, and CD45+CD235a- cells from blood after density gradient separation. Cells were screened for TSC2 LOH at five microsatellites markers (ie, kg8, D16S3395, D16S3024, D16S521, D16S291). We obtained four cell subpopulations from urine (ie, CD44v6+CD9+, CD44v6+CD9-, CD44v6-CD9+, CD44v6-CD9-).Using FACS, cells were isolated from blood and urine from patients with PLCH that showed TSC2 LOH. Healthy volunteers did not have cells with TSC2 LOH. As a control, cells isolated from blood and urine from patients with LAM gave results similar to those reported previously. These data show that TSC2 LOH is found in patients with cystic lung diseases with potential neoplastic characteristics, and in patients with cancer.The presence of TSC2 LOH in circulating cells is not specific for LAM. The data suggest that chromosomal abnormalities affecting the TSC2 gene are found in other diseases associated with cells having cancer-like neoplastic cells.
- Published
- 2022
3. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells
- Author
-
Elizabeth P. Henske, Ivan O. Rosas, Shefali Bagwe, Yan Tang, Angelo M. Taveira-DaSilva, Joel Moss, Hilary J. Goldberg, Souheil El-Chemaly, and Carmen Priolo
- Subjects
Pulmonary and Respiratory Medicine ,Lung Neoplasms ,mTORC1 ,Critical Care and Intensive Care Medicine ,03 medical and health sciences ,0302 clinical medicine ,Downregulation and upregulation ,Tuberous Sclerosis Complex 2 Protein ,Polyamines ,Tumor Cells, Cultured ,Metabolome ,Humans ,Medicine ,Lymphangioleiomyomatosis ,030212 general & internal medicine ,Sirolimus ,Antibiotics, Antineoplastic ,business.industry ,Hydroxychloroquine ,medicine.disease ,medicine.anatomical_structure ,030228 respiratory system ,Cancer research ,Female ,TSC1 ,Diffuse Lung Disease ,TSC2 ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
Background Lymphangioleiomyomatosis (LAM), a destructive lung disease that affects primarily women, is caused by loss-of-function mutations in TSC1 or TSC2, leading to hyperactivation of mechanistic/mammalian target of rapamycin complex 1 (mTORC1). Rapamycin (sirolimus) treatment suppresses mTORC1 but also induces autophagy, which promotes the survival of TSC2-deficient cells. Based on the hypothesis that simultaneous inhibition of mTORC1 and autophagy would limit the availability of critical nutrients and inhibit LAM cells, we conducted a phase 1 clinical trial of sirolimus and hydroxychloroquine for LAM. Here, we report the analyses of plasma metabolomic profiles from the clinical trial. Methods We analyzed the plasma metabolome in samples obtained before, during, and after 6 months of treatment with sirolimus and hydroxychloroquine, using univariate statistical models and machine learning approaches. Metabolites and metabolic pathways were validated in TSC2-deficient cells derived from patients with LAM. Single-cell RNA-Seq was employed to assess metabolic enzymes in an early-passage culture from an LAM lung. Results Metabolomic profiling revealed changes in polyamine metabolism during treatment, with 5′-methylthioadenosine and arginine among the most highly upregulated metabolites. Similar findings were observed in TSC2-deficient cells derived from patients with LAM. Single-cell transcriptomic profiling of primary LAM cultured cells revealed that mTORC1 inhibition upregulated key enzymes in the polyamine metabolism pathway, including adenosylmethionine decarboxylase 1. Conclusions Our data demonstrate that polyamine metabolic pathways are targeted by the combination of rapamycin and hydroxychloroquine, leading to upregulation of 5′-methylthioadenosine and arginine in the plasma of patients with LAM and in TSC2-deficient cells derived from a patient with LAM upon treatment with this drug combination. Trial Registry ClinicalTrials.gov; No.: NCT01687179; URL: www.clinicaltrials.gov. Partners Human Research Committee, protocol No. 2012P000669.
- Published
- 2019
4. Use of CT Imaging to Quantify Progression and Response to Treatment in Lymphangioleiomyomatosis
- Author
-
Vissaagan Gopalakrishnan, Joel Moss, Nilo A. Avila, Wendy K. Steagall, Marcus Y. Chen, Jianhua Yao, Mario Stylianou, and Angelo M. Taveira-DaSilva
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,Lung Neoplasms ,Critical Care and Intensive Care Medicine ,Risk Assessment ,DLCO ,Multidetector Computed Tomography ,Parenchyma ,Humans ,Medicine ,Cyst ,Longitudinal Studies ,Lymphangioleiomyomatosis ,Sirolimus ,Lung ,Cysts ,business.industry ,Middle Aged ,respiratory system ,Prognosis ,medicine.disease ,Response to treatment ,Cross-Sectional Studies ,Treatment Outcome ,medicine.anatomical_structure ,Disease Progression ,Female ,Diffuse Lung Disease ,Ct imaging ,Cardiology and Cardiovascular Medicine ,business ,Nuclear medicine ,medicine.drug - Abstract
BACKGROUND: In lymphangioleiomyomatosis (LAM), infiltration of the lungs with smooth muscle-like LAM cells results in cystic destruction and decline in lung function, effects stabilized by sirolimus therapy. LAM lung disease is followed, in part, by high-resolution CT scans. To obtain further information from these scans, we quantified changes in lung parenchyma by analyzing image “texture.” METHODS: Twenty-six texture properties were quantified by analyzing the distribution and intensity of pixels with a computer-aided system. Both cross-sectional and longitudinal studies were performed to examine the relationships between texture properties, cyst score (percentage of lung occupied by cysts), FEV(1), and diffusion capacity for carbon monoxide (Dlco), and to determine the effect of sirolimus treatment. RESULTS: In the cross-sectional study, 18 texture properties showed significant positive correlations with cyst score. Cyst score and 13 of the 18 texture properties showed significant differences in rates of change after sirolimus treatment; 11 also significantly predicted FEV(1) and Dlco. CONCLUSIONS: Increased cyst score was associated with increased texture degradation near cysts. Sirolimus treatment improved lung texture surrounding cysts and stabilized cyst score. Eleven texture properties were associated with FEV(1), Dlco, cyst score, and response to sirolimus. Texture analysis may be valuable in evaluating LAM severity and treatment response.
- Published
- 2019
5. Chest CT Scan at Radiation Dose of a Posteroanterior and Lateral Chest Radiograph Series
- Author
-
Tania Machado, Eileen Hu-Wang, Marcus Y. Chen, Amanda M. Jones, Chloe Steveson, Joel Moss, John L. Schuzer, Patricia Julien-Williams, Jianhua Yao, Vissaagan Gopalakrishnan, Shirley F. Rollison, and Eric S. Leifer
- Subjects
Pulmonary and Respiratory Medicine ,Percentile ,Lung ,business.industry ,Equivalent dose ,Radiography ,Chest ct ,Critical Care and Intensive Care Medicine ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,030228 respiratory system ,Lymphangioleiomyomatosis ,Medical imaging ,Medicine ,Cyst ,030212 general & internal medicine ,Cardiology and Cardiovascular Medicine ,business ,Nuclear medicine - Abstract
Background Given the rising utilization of medical imaging and the risks of radiation, there is increased interest in reducing radiation exposure. The objective of this study was to evaluate, as a proof of principle, CT scans performed at radiation doses equivalent to that of a posteroanterior and lateral chest radiograph series in the cystic lung disease lymphangioleiomyomatosis (LAM). Methods From November 2016 to May 2018, 105 consecutive subjects with LAM received chest CT scans at standard and ultra-low radiation doses. Standard and ultra-low-dose images, respectively, were reconstructed with routine iterative and newer model-based iterative reconstruction. LAM severity can be quantified as cyst score (percentage of lung occupied by cysts), an ideal benchmark for validating CT scans performed at a reduced dose compared with a standard dose. Cyst scores were quantified using semi-automated software and evaluated by linear correlation and Bland-Altman analysis. Results Overall, ultra-low-dose CT scans represented a 96% dose reduction, with a median dose equivalent to 1 vs 22 posteroanterior and lateral chest radiograph series (0.14 mSv; 5th-95th percentile, 0.10-0.20 vs standard dose 3.4 mSv; 5th-95th percentile, 1.5-7.4; P Conclusions In LAM chest CT scan at substantial radiation reduction to doses equivalent to that of a posteroanterior and lateral chest radiograph series provides cyst score quantification similar to that of standard-dose CT scan. Trial Registry ClinicalTrials.gov; Nos.: NCT00001465 and NCT00001532 ; URL: www.clinicaltrials.gov .
- Published
- 2019
6. The NHLBI LAM Registry
- Author
-
Joel Moss, Kevin McCarthy, Hye-Seung Lee, Jay H. Ryu, Nishant Gupta, Nilo A. Avila, Geraldine A. Finlay, Kevin K. Brown, Stephen J. Ruoss, Angelo M. Taveira-DaSilva, Gerald J. Beck, Jar-Chi Lee, and Francis X. McCormack
- Subjects
Pulmonary and Respiratory Medicine ,Prognostic variable ,medicine.medical_specialty ,Proportional hazards model ,business.industry ,medicine.medical_treatment ,Hazard ratio ,Retrospective cohort study ,Critical Care and Intensive Care Medicine ,medicine.disease ,Lower risk ,Pulmonary function testing ,Internal medicine ,Lymphangioleiomyomatosis ,medicine ,Lung transplantation ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background The natural history of lymphangioleiomyomatosis (LAM) is mainly derived from retrospective cohort analyses, and it remains incompletely understood. A National Institutes of Health LAM Registry was established to define the natural history and identify prognostic biomarkers that can help guide management and decision-making in patients with LAM. Methods A linear mixed effects model was used to compute the rate of decline of FEV1 and to identify variables affecting FEV1 decline among 217 registry patients who enrolled from 1998 to 2001. Prognostic variables associated with progression to death/lung transplantation were identified by using a Cox proportional hazards model. Results Mean annual decline of FEV1 was 89 ± 53 mL/year and remained remarkably constant regardless of baseline lung function. FEV1 decline was more rapid in those with greater cyst profusion on CT scanning (P = .02) and in premenopausal subjects (118 mL/year) compared with postmenopausal subjects (74 mL/year) (P = .003). There were 26 deaths and 43 lung transplantations during the evaluation period. The estimated 5-, 10-, 15-, and 20-year transplant-free survival rates were 94%, 85%, 75%, and 64%, respectively. Postmenopausal status (hazard ratio, 0.30; P = .0002) and higher baseline FEV1 (hazard ratio, 0.97; P = .008) or diffusion capacity of lung for carbon monoxide (hazard ratio, 0.97; P = .001) were independently associated with a lower risk of progression to death or lung transplantation. Conclusions The median transplant-free survival in patients with LAM is > 20 years. Menopausal status, as well as structural and physiologic markers of disease severity, significantly affect the rate of decline of FEV1 and progression to death or lung transplantation in LAM.
- Published
- 2019
7. Implications of the Revised Common Rule for Human Participant Research
- Author
-
Joel Moss, Evan G. DeRenzo, and Eric A. Singer
- Subjects
Pulmonary and Respiratory Medicine ,Research ethics ,Biomedical Research ,Informed Consent ,Research Subjects ,business.industry ,Corporate governance ,Human subject research ,Critical Care and Intensive Care Medicine ,Institutional review board ,United States ,Office for Human Research Protections ,Research Design ,Code of Federal Regulations ,Informed consent ,Law ,Common Rule ,Humans ,Medicine ,Policy Making ,Cardiology and Cardiovascular Medicine ,business ,Ahead of the Curve ,Needs Assessment ,Ethics Committees, Research - Abstract
This paper looks at the implications of changes to the regulatory governance of human participant research that can be expected with implementation of the Revised Common Rule (RCR). The RCR refers to revisions of the existing federal regulations that govern the performance of research involving human subjects (ie, clinical research) in the United States and, under certain circumstances, when such research is also performed outside the United States. The term "common" is included because it refers to the fact that these regulations, often referred to as Code of Federal Regulations 46, is the common denominator regulations agreed to across a wide swath of federal agencies.
- Published
- 2019
8. Spread the Word About CHEST in 2019
- Author
-
Richard S. Irwin, John E. Heffner, Lisbeth Maxwell, Cynthia L. French, Nicki Augustyn, Julie Frantsve-Hawley, Peter J. Barnes, Christopher E. Brightling, Bruce L. Davidson, David D. Gutterman, Jesse B. Hall, Nicholas S. Hill, Robert G. Johnson, Scott Manaker, Reena Mehra, Joel Moss, Susan Murin, Paul M. O’Byrne, Bruce K. Rubin, Marvin I. Schwarz, Barbara Anderson, Laura Lipsey, Carla Miller, Pamela Goorsky, Robert Musacchio, Floris Dirk de Hon, Pamela Poppalardo, Kelly Adamitis, Cynthia Clark, Eileen Fournier, Michelle Nightlinger, Shelly Nuttall, Matthew Richardson, Nancy Rolya, Dan Schottenfeld, Adam Segal-Isaacson, Matthew Tomasheski, Jean Rice, and Steve Welch
- Subjects
Pulmonary and Respiratory Medicine ,business.industry ,MEDLINE ,Medicine ,Cardiology and Cardiovascular Medicine ,Critical Care and Intensive Care Medicine ,business ,Linguistics ,Word (computer architecture) - Published
- 2019
9. Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis
- Author
-
Ye Cui, Souheil El-Chemaly, Shefali Bagwe, Ivan O. Rosas, Elizabeth P. Henske, Hilary J. Goldberg, Joel Moss, Angelo M. Taveira-DaSilva, and Anthony M. Lamattina
- Subjects
Adult ,Lung Diseases ,0301 basic medicine ,Pulmonary and Respiratory Medicine ,Oncology ,medicine.medical_specialty ,Lung injury ,Critical Care and Intensive Care Medicine ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Lymphangioleiomyomatosis ,Enzyme Inhibitors ,KEGG ,Correlation of Data ,PI3K/AKT/mTOR pathway ,Sirolimus ,business.industry ,Fibrinogen ,Hydroxychloroquine ,Vascular Endothelial Growth Factor Receptor-3 ,medicine.disease ,Respiratory Function Tests ,Vascular endothelial growth factor ,030104 developmental biology ,chemistry ,030220 oncology & carcinogenesis ,Rheumatoid arthritis ,Drug Therapy, Combination ,Female ,Diffuse Lung Disease ,Drug Monitoring ,Cardiology and Cardiovascular Medicine ,business ,Biomarkers ,Immunosuppressive Agents ,Acetyl-CoA Carboxylase ,medicine.drug - Abstract
Background We have previously conducted the Sirolimus and Autophagy Inhibition in LAM (SAIL) trial, a phase 1 dose-escalation study of the combination of sirolimus and hydroxychloroquine in patients with lymphangioleiomyomatosis (LAM). The goal of the present study was to analyze sera from the SAIL trial to identify novel biomarkers that could shed light into disease pathogenesis and response to therapy. Methods We used the DiscoveryMAP platform from Rules Based Medicine to simultaneously measure 279 analytes in sera collected at each visit from subjects enrolled in the SAIL trial. We used longitudinal regression and pathway analysis to examine analyte rate of change and corresponding effect on lung function and to identify networks and potential nodes of interest. Results A total of 222 analytes were included in the analysis. We identified 32 analytes that changed over the treatment period of the study. Pathway analysis revealed enrichment in cytokine-receptor interaction and mechanistic/mammalian target of rapamycin-related pathways, in addition to seemingly unrelated processes such as rheumatoid arthritis. Search Tool for the Retrieval of Interacting Genes/Proteins analysis identified two hubs centered around acetyl-CoA carboxylase alpha and beta and coagulation factor II. In addition, we identified vascular endothelial growth factor receptor-3 and CCL21 as molecules significantly associated with changes in FEV1 during the study period. Conclusions We performed a large-scale analyte study in sera of women with LAM and identified potential markers that could be linked to disease pathogenesis, lung injury, and therapeutic response. These data will enable future investigation into the specific roles of these molecules in LAM. Trial Registry ClinicalTrials.gov; No. NCT01687179 ; URL: www.clinicaltrials.gov ).
- Published
- 2018
10. Ultra-Small Lung Cysts Impair Diffusion Without Obstructing Air Flow in Lymphangioleiomyomatosis
- Author
-
Shirley F. Rollison, B. Matthew, Angelo M. Taveira-DaSilva, Joel Moss, Nora M. Quade, A. Hasani, Marcus Y. Chen, Amanda M. Jones, Patricia Julien-Williams, Yun-Ching Chen, Mario Stylianou, Tania Machado, Han Wen, and Mehdi Pirooznia
- Subjects
Pulmonary and Respiratory Medicine ,Lung Neoplasms ,Critical Care and Intensive Care Medicine ,Pulmonary function testing ,rUHRCT, regional ultra-high resolution CT ,Diffusion ,03 medical and health sciences ,FEV1/FVC ratio ,LAM, lymphangioleiomyomatosis ,0302 clinical medicine ,DLCO ,Diffusing capacity ,parasitic diseases ,Medicine ,Humans ,Lung volumes ,Cyst ,030212 general & internal medicine ,Lymphangioleiomyomatosis ,Lung ,Lung cysts ,Work of Breathing ,business.industry ,Cysts ,respiratory system ,medicine.disease ,respiratory tract diseases ,Respiratory Function Tests ,PFT, pulmonary function test ,Airway Obstruction ,030228 respiratory system ,Printing, Three-Dimensional ,Diffuse Lung Disease: Original Research ,Artificial Organs ,Cardiology and Cardiovascular Medicine ,business ,Nuclear medicine ,Tomography, X-Ray Computed ,TSC, tuberous sclerosis complex ,circulatory and respiratory physiology ,Dlco, diffusing capacity of the lungs for carbon monoxide - Abstract
BACKGROUND Lymphangioleiomyomatosis (LAM) is a rare lung disease found primarily in women of childbearing age, characterized by the formation of air-filled cysts, which may be associated with reductions in lung function. An experimental, regional ultra-high resolution CT scan identified an additional volume of cysts relative to standard chest CT imaging, which consisted primarily of ultra-small cysts. RESEARCH QUESTION What is the impact of these ultra-small cysts on the pulmonary function of patients with LAM? STUDY DESIGN AND METHODS A group of 103 patients with LAM received pulmonary function tests and a CT examination in the same visit. Cyst score, the percentage lung volume occupied by cysts, was measured by using commercial software approved by the US Food and Drug Administration. The association between cyst scores and pulmonary function tests of diffusing capacity of the lungs for carbon monoxide (Dlco) (% predicted), FEV1 (% predicted), and FEV1/FVC (% predicted) was assessed with statistical analysis adjusted for demographic variables. The distributions of average cyst size and ultra-small cyst fraction among the patients were evaluated. RESULTS The additional cyst volume identified by the experimental, higher resolution scan consisted of cysts of 2.2 ± 0.8 mm diameter on average and are thus labeled the "ultra-small cyst fraction." It accounted for 27.9 ± 19.0% of the total cyst volume among the patients. The resulting adjusted, whole-lung cyst scores better explained the variance of Dlco (P < .001 adjusted for multiple comparisons) but not FEV1 and FEV1/FVC (P = 1.00). The ultra-small cyst fraction contributed to the reduction in Dlco (P < .001) but not to FEV1 and FEV1/FVC (P = .760 and .575, respectively). The ultra-small cyst fraction and average cyst size were correlated with cyst burden, FEV1, and FEV1/FVC but less with Dlco. INTERPRETATION The ultra-small cysts primarily contributed to the reduction in Dlco, with minimal effects on FEV1 and FEV1/FVC. Patients with lower cyst burden and better FEV1 and FEV1/FVC tended to have smaller average cyst size and higher ultra-small cyst fraction. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov; No.: NCT00001465; URL: www.clinicaltrials.gov.
- Published
- 2020
11. Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis
- Author
-
Ivan O. Rosas, Souheil El-Chemaly, Patricia Julien-Williams, Mary Haughey, Ye Cui, Angelo M. Taveira-DaSilva, Hilary J. Goldberg, Amanda M. Jones, Rie Maurer, Don C. Bienfang, Elizabeth Peters, Joel Moss, Shefali Bagwe, Elizabeth P. Henske, and Julian A. Villalba
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,business.industry ,Phases of clinical research ,Hydroxychloroquine ,Critical Care and Intensive Care Medicine ,medicine.disease ,Pulmonary function testing ,Surgery ,03 medical and health sciences ,FEV1/FVC ratio ,030104 developmental biology ,0302 clinical medicine ,030228 respiratory system ,Sirolimus ,Internal medicine ,Lymphangioleiomyomatosis ,Mucositis ,medicine ,Cardiology and Cardiovascular Medicine ,Adverse effect ,business ,medicine.drug - Abstract
Background Animal and cellular studies support the importance of autophagy inhibition in lymphangioleiomyomatosis (LAM). In a cohort of subjects with LAM, we tested the hypothesis that treatment with sirolimus and hydroxychloroquine (an autophagy inhibitor) at two different dose levels is safe and well tolerated. Secondary end points included changes in lung function. Methods This 48-week, two-center phase I trial evaluated the safety of escalating oral hydroxychloroquine doses (100-200 mg) given twice a day in combination with sirolimus to eligible patients ≥ 18 years old with LAM. Subjects received combination therapy for 24 weeks followed by an observation phase without taking study drugs for an additional 24 weeks. Results Fourteen patients provided written informed consent. Thirteen were treated in cohorts of three patients each with escalating hydroxychloroquine doses (200 and 400 mg) and an extension phase at the 400-mg dose. The most common adverse events were mucositis, headache, and diarrhea. No drug-related serious adverse events were reported. Secondary end points showed improvement in lung function at 24 weeks, with a decrease in lung function at the 48-week time point. When the higher dose of hydroxychloroquine was analyzed separately, FEV 1 and FVC remained stable at 48 weeks, but the 6-min walk distance showed a decrease toward baseline. Conclusions The combination of sirolimus and hydroxychloroquine is well tolerated, with no dose-limiting adverse events observed at 200 mg twice a day. Potential effects on lung function should be explored in larger trials. Trial Registry ClinicalTrials.gov; No.: NCT01687179; URL: www.clinicaltrials.gov
- Published
- 2017
12. Effect of Fasting on the Size of Lymphangioleiomyomas in Patients With Lymphangioleiomyomatosis
- Author
-
Patricia Julien-Williams, Mario Stylianou, Amanda M. Jones, Thomas H. Shawker, Angelo M. Taveira-DaSilva, Connie G. Glasgow, and Joel Moss
- Subjects
Adult ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Pathology ,Chyle ,Vascular Endothelial Growth Factor D ,Critical Care and Intensive Care Medicine ,Malignancy ,Severity of Illness Index ,Gastroenterology ,Interquartile range ,Diffusing capacity ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Ingestion ,Lymphangioleiomyomatosis ,Neoplasm Staging ,Original Research ,Lung ,business.industry ,Fasting ,medicine.disease ,medicine.anatomical_structure ,Lymphatic system ,Abdominal Neoplasms ,Female ,Tomography, X-Ray Computed ,Cardiology and Cardiovascular Medicine ,business ,Lymphangiomyoma ,Follow-Up Studies - Abstract
Lymphangioleiomyomas occur in 38% of patients with sporadic lymphangioleiomyomatosis (LAM) and may cause pain and increased abdominal girth, mimicking the presence of a malignancy. Lymphatic involvement in LAM is closely associated with elevated serum levels of vascular endothelium growth factor-D (VEGF-D). Because lymphangioleiomyomas undergo diurnal variation in volume, we hypothesized that daytime ingestion of food, by increasing chyle formation and lymphatic flow, is the cause of an increase in lymphangioleiomyoma volume.Subjects had abdominopelvic sonograms and blood drawn for measurement of serum VEGF-D levels under nonfasting (day 1) and fasting (day 2) conditions. The size of the lymphangioleiomyomas was determined by a radiologist who was blinded to the subjects' status. The Wilcoxon signed rank test was used to determine whether the nonfasting tumor size was different from the fasting tumor size.Thirty-five women were studied (aged 45.2 ± 8.5 years; FEV1, 82% ± 25%; diffusing capacity of the lung for carbon monoxide, 64% ± 25% predicted). Images suitable for volume measurements were obtained in 30 subjects. Fasting decreased the tumor size by 20.7 ± 39.3 cm3 (24% ± 40%, P.001). Fasting VEGF-D levels (10,650 ± 900 pg/mL) were not significantly different from nonfasting values (12,100 ± 800 pg/mL, P = .56).Lymphangioleiomyoma volume decreased during the fasting state. Conversely, a combination of food intake and decreased chyle flow through lymphatics partially obstructed by LAM cells may account for increases in lymphangioleiomyoma size. Imaging studies performed under fasting conditions may help in determining whether an abdominal tumor is a result of LAM or malignancy.
- Published
- 2015
13. Antibody αPEP13h Reacts With Lymphangioleiomyomatosis Cells in Lung Nodules
- Author
-
Patricia Fetsch, Julio C. Valencia, Eric M. Billings, Katsuya Tsukada, Yi Zhang, Andrea Abati, Zu-Xi Yu, Wendy K. Steagall, Vincent J. Hearing, Joel Moss, and Gustavo Pacheco-Rodriguez
- Subjects
Adult ,Pulmonary and Respiratory Medicine ,Pathology ,medicine.medical_specialty ,Lung Neoplasms ,medicine.drug_class ,Biopsy ,Critical Care and Intensive Care Medicine ,Monoclonal antibody ,Sensitivity and Specificity ,Diagnosis, Differential ,Tuberous sclerosis ,immune system diseases ,hemic and lymphatic diseases ,Bronchoscopy ,medicine ,Humans ,Lymphangioleiomyomatosis ,Lung ,Cells, Cultured ,Original Research ,Melanoma-associated antigen ,biology ,Solitary Pulmonary Nodule ,Middle Aged ,bacterial infections and mycoses ,medicine.disease ,Immunohistochemistry ,Antibodies, Anti-Idiotypic ,HMB-45 ,Lymphatic system ,biology.protein ,Female ,lipids (amino acids, peptides, and proteins) ,Antibody ,Cardiology and Cardiovascular Medicine ,Melanoma-Specific Antigens ,gp100 Melanoma Antigen - Abstract
BACKGROUND Lymphangioleiomyomatosis (LAM) is characterized by the proliferation in the lung, axial lymphatics (eg, lymphangioleiomyomas), and kidney (eg, angiomyolipomas) of abnormal smooth muscle-like LAM cells, which express melanoma antigens such as Pmel17/gp100 and have dysfunctional tumor suppressor tuberous sclerosis complex (TSC) genes TSC2 or TSC1 . Histopathologic diagnosis of LAM in lung specimens is based on identification of the Pmel17 protein with the monoclonal antibody HMB-45. METHODS We compared the sensitivity of HMB-45 to that of antipeptide antibody αPEP13h, which reacts with a C-terminal peptide of Pmel17. LAM lung nodules were laser-capture microdissected to identify proteins by Western blotting. RESULTS HMB-45 recognized approximately 25% of LAM cells within the LAM lung nodules, whereas αPEP13h identified > 82% of LAM cells within these structures in approximately 90% of patients. Whereas HMB-45 reacted with epithelioid but not with spindle-shaped LAM cells, αPEP13h identified both spindle-shaped and epithelioid LAM cells, providing greater sensitivity for detection of all types of LAM cells. HMB-45 recognized Pmel17 in premelanosomal organelles; αPEP13h recognized proteins in the cytoplasm as well as in premelanosomal organelles. Both antibodies recognized a Pmel17 variant of approximately 50 kDa. CONCLUSIONS Based on its sensitivity and specificity, αPEP13h may be useful in the diagnosis of LAM and more sensitive than HMB-45.
- Published
- 2015
14. Mounier-Kuhn Syndrome Mimicking Lymphangioleiomyomatosis
- Author
-
Amanda M. Jones, Joel Moss, David E. Kleiner, Angelo M. Taveira-DaSilva, Jianhua Yao, and Gustavo G. Pacheco
- Subjects
Pulmonary and Respiratory Medicine ,Tracheobronchomegaly ,Adult ,Male ,Pathology ,medicine.medical_specialty ,Nitrogen washout test ,Critical Care and Intensive Care Medicine ,Diagnosis, Differential ,03 medical and health sciences ,0302 clinical medicine ,DLCO ,Parenchyma ,Medicine ,Anatomic dead space ,Humans ,Lymphangioleiomyomatosis ,Lung ,Parenchymal Tissue ,business.industry ,Selected Report ,respiratory system ,medicine.disease ,Lung diffusion capacity ,030228 respiratory system ,Mounier-Kuhn syndrome ,Cardiology and Cardiovascular Medicine ,business ,Tomography, X-Ray Computed ,030217 neurology & neurosurgery - Abstract
We present the case of a man with Mounier-Kuhn syndrome (MKS), or tracheobronchomegaly, who was referred to the National Institutes of Health Clinical Research Center because of a potential diagnosis of lymphangioleiomyomatosis (LAM), a rare condition in men. The patient was evaluated using ongoing protocols and provided written informed consent. The case demonstrates the presence of chronic inflammation surrounding the dilated airways and histologic changes of the lung parenchyma with emphysematouslike disruption in areas adjacent to the dilated airways. This finding suggests that damage to the lung parenchyma is an ongoing phenomenon in MKS. Moreover, our analysis of CT images indicates similar abnormalities in areas remote from the dilated airways. Finally, because of increased anatomic dead space, calculation of lung diffusion capacity by the single-breath method yielded abnormally low values that required making a correction for the large anatomic dead space, which can be measured by the single-breath nitrogen washout test.
- Published
- 2017
15. CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis
- Author
-
Patricia Julien-Williams, Connie G. Glasgow, Wendy K. Steagall, Mario Stylianou, Mary Haughey, Gustavo Pacheco-Rodriguez, Bernadette R. Gochuico, and Joel Moss
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,Pathology ,medicine.medical_specialty ,Angiomyolipoma ,Pleural effusion ,Critical Care and Intensive Care Medicine ,03 medical and health sciences ,Idiopathic pulmonary fibrosis ,Young Adult ,0302 clinical medicine ,immune system diseases ,hemic and lymphatic diseases ,medicine ,Humans ,Lymphangioleiomyomatosis ,Aged ,Aged, 80 and over ,Sirolimus ,Analysis of Variance ,Lung ,business.industry ,Mucins ,Middle Aged ,bacterial infections and mycoses ,medicine.disease ,Immunohistochemistry ,Respiratory Function Tests ,Pleural Effusion ,medicine.anatomical_structure ,030228 respiratory system ,030220 oncology & carcinogenesis ,CA-125 Antigen ,Disease Progression ,Biomarker (medicine) ,lipids (amino acids, peptides, and proteins) ,Female ,Diffuse Lung Disease ,Cardiology and Cardiovascular Medicine ,Ovarian cancer ,business ,Biomarkers ,Immunosuppressive Agents ,medicine.drug - Abstract
Background Lymphangioleiomyomatosis (LAM) is a destructive lung disease of women caused by proliferation of neoplastic-like LAM cells, with mutations in the TSC1/2 tumor suppressor genes. Based on case reports, levels of cancer antigen 125 (CA-125), an ovarian cancer biomarker, can be elevated in patients with LAM. We hypothesized that elevated serum CA-125 levels seen in some patients with LAM were due to LAM, not other malignancies, and might respond to sirolimus treatment. Methods Serum CA-125 levels were measured for 241 patients at each visit. Medical records were reviewed for co-morbidities, disease progression, and response to sirolimus treatment. CA-125 expression in LAM cells was determined by using immunohistochemical analysis. Results Almost 25% of patients with LAM had at least one elevated serum CA-125 measurement. Higher serum CA-125 levels correlated with lower FEV 1 , premenopausal status, and pleural effusion in a multivariate model (each P P = .002). CA-125 and α-smooth muscle actin were co-expressed in LAM lung nodules. Conclusions Higher serum CA-125 levels were associated with pleural effusions and reduced pulmonary function and were decreased with sirolimus therapy. LAM cells express CA-125. Some elevated serum CA-125 levels may reflect serosal membrane involvement.
- Published
- 2017
16. Sirolimus Decreases Circulating Lymphangioleiomyomatosis Cells in Patients With Lymphangioleiomyomatosis
- Author
-
Suowen Xu, J. Philip McCoy, Gustavo Pacheco-Rodriguez, Joel Moss, Mario Stylianou, Mary Haughey, Thomas N. Darling, Hai-Ping Wu, Xiong Cai, and Leigh Samsel
- Subjects
Adult ,Pulmonary and Respiratory Medicine ,Pathology ,medicine.medical_specialty ,Angiomyolipoma ,Loss of Heterozygosity ,Critical Care and Intensive Care Medicine ,Loss of heterozygosity ,Tuberous sclerosis ,hemic and lymphatic diseases ,Tuberous Sclerosis Complex 2 Protein ,medicine ,Humans ,Lymphangioleiomyomatosis ,Original Research ,Sirolimus ,Antibiotics, Antineoplastic ,Lung ,biology ,business.industry ,Tumor Suppressor Proteins ,Middle Aged ,Neoplastic Cells, Circulating ,medicine.disease ,Lymphatic system ,medicine.anatomical_structure ,biology.protein ,Female ,Antibody ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies ,medicine.drug - Abstract
Background Lymphangioleiomyomatosis (LAM), sporadic or in women with tuberous sclerosis complex (TSC), is characterized by cystic lung destruction, lymphatic involvement (eg, chylous pleural effusions, lymphangioleiomyomas), and renal angiomyolipomas (AMLs). The multisystem manifestations of LAM appear to result from metastatic dissemination of LAM cells bearing inactivating mutations or having loss of heterozygosity (LOH) of the tumor suppressor genes TSC1 or TSC2 , which leads to hyperactivation of the mammalian target of rapamycin. Sirolimus slows the decline of lung function, reduces chylous effusions, and shrinks the size of AMLs. The purpose of this study was to determine the effect of sirolimus on circulating LAM cells. Methods Cells from blood were isolated by a density-gradient fractionation system and from urine and chylous effusions by centrifugation. Blood cells were incubated with anti-CD45-fluorescein isothiocyanate (FITC) and anti-CD235a-R-phycoerythrin (PE) antibodies, and urine and chylous effusion cells were incubated with anti-CD44v6-FITC and anti-CD9-R-PE antibodies. Cells were sorted and analyzed for TSC2 LOH. Results LAM cells with TSC2 LOH were identified in 100% of blood specimens and 75% of urine samples from patients before therapy. Over a mean duration of 2.2 ± 0.4 years of sirolimus therapy, detection rates of LAM cells were significantly decreased to 25% in blood ( P P = .003). Following therapy, a greater loss of circulating LAM cells was seen in postmenopausal patients ( P = .025). Conclusions Patients receiving sirolimus had a progressive loss of circulating LAM cells that depended on time of treatment and menopausal status.
- Published
- 2014
17. Glucose Transporter-1 Distribution in Fibrotic Lung Disease
- Author
-
Joel Moss, Bernadette R. Gochuico, Daniela Malide, Jianhua Yao, Souheil El-Chemaly, Steven D. Nathan, Ivan O. Rosas, and William A. Gahl
- Subjects
Pulmonary and Respiratory Medicine ,Pathology ,medicine.medical_specialty ,Lung ,business.industry ,Glucose transporter ,Inflammation ,respiratory system ,Critical Care and Intensive Care Medicine ,medicine.disease ,respiratory tract diseases ,carbohydrates (lipids) ,Neovascularization ,Idiopathic pulmonary fibrosis ,medicine.anatomical_structure ,Fibrosis ,Pulmonary fibrosis ,medicine ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Glucose Transporter Type 1 - Abstract
Background [ 18 F]-2-fluoro-2-deoxyglucose (FDG)-PET scan uptake is increased in areas of fibrosis and honeycombing in patients with idiopathic pulmonary fibrosis (IPF). Glucose transporter-1 (Glut-1) is known to be the main transporter for FDG. There is a paucity of data regarding the distribution of Glut-1 and the cells responsible for FDG binding in fibrotic lung diseases. Methods We applied immunofluorescence to localize Glut-1 in normal, IPF, and Hermansky-Pudlak syndrome (HPS) pulmonary fibrosis lung tissue specimens as well as an array of 19 different lung neoplasms. In addition, we investigated Glut-1 expression in inflammatory cells from BAL fluid (BALF) from healthy volunteers, subjects with IPF, and subjects with HPS pulmonary fibrosis. Results In normal lung tissue, Glut-1 immunoreactivity was seen on the surface of erythrocytes. In tissue sections from fibrotic lung diseases (IPF and HPS pulmonary fibrosis), Glut-1 immunoreactivity was present on the surface of erythrocytes and inflammatory cells. BALF inflammatory cells from healthy control subjects showed no immunoreactivity; BALF cells from subjects with IPF and HPS pulmonary fibrosis showed Glut-1 immunoreactivity associated with neutrophils and alveolar macrophages. Conclusions Glut-1 transporter expression in normal lung is limited to erythrocytes. In fibrotic lung, erythrocytes and inflammatory cells express Glut-1. Together, these data suggest that FDG-PET scan uptake in IPF could be explained by enhanced inflammatory and erythrocytes uptake due to neovascularization seen in IPF and not an upregulation of metabolic rate in pneumocytes. Thus, FDG-PET scan may detect inflammation and neovascularization in lung fibrosis.
- Published
- 2013
18. Reversible Airflow Obstruction in Lymphangioleiomyomatosis
- Author
-
Wendy K. Steagall, Roberto Cassandro, Angelo M. Taveira-DaSilva, Joel Moss, Olanda Hathaway, Sergio Harari, Antoinette Rabel, and Mario Stylianou
- Subjects
Adult ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,medicine.drug_class ,Vital Capacity ,Critical Care and Intensive Care Medicine ,Cholinergic Antagonists ,White People ,Pulmonary function testing ,FEV1/FVC ratio ,immune system diseases ,Internal medicine ,Forced Expiratory Volume ,Diffusing capacity ,Bronchodilator ,Humans ,Medicine ,Albuterol ,Lymphangioleiomyomatosis ,Prospective cohort study ,Original Research ,Aged ,Retrospective Studies ,Asthma ,Aged, 80 and over ,Asian ,business.industry ,Ipratropium ,Hispanic or Latino ,Adrenergic beta-Agonists ,Middle Aged ,medicine.disease ,Bronchodilator Agents ,respiratory tract diseases ,Black or African American ,Treatment Outcome ,Anesthesia ,Cardiology ,Pulmonary Ventilation ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background We previously reported that approximately one-fourth of patients with lymphangioleiomyomatosis (LAM) may respond to therapy with bronchodilators. However, the validity of those observations has been questioned. The aims of the present study were to determine the prevalence of reversible airflow obstruction in patients with LAM and to identify associated clinical and physiologic parameters. Methods First, the clinical and physiologic characteristics of 235 patients were analyzed to determine the frequency of the response to albuterol during a total of 2,307 visits. Second, we prospectively evaluated the response to albuterol (2.5 mg) and ipratropium (500 μg) in 130 patients, and correlated their responses with their clinical and physiologic characteristics. Results In the retrospective study, 51% of the patients responded at least once to bronchodilators; of these, 12% responded ≥ 50% of the time. A higher frequency of positive bronchodilator responses was associated with greater rates of decline in FEV1 and diffusing capacity of the lung for carbon monoxide (D lco ). In the prospective study, 39 patients (30%) responded to bronchodilators, including 12 to ipratropium, 9 to albuterol, and 18 to both. The prevalence of asthma and smoking in the 39 responders was not different from that seen in the 91 nonresponders. Patients who responded to ipratropium, albuterol, or both had significantly (p lco, and a greater rate of FEV1 decline (p = 0.044) and D lco decline (p = 0.039) than patients who did not respond to these bronchodilators. After adjusting for FEV1/FVC ratio, D lco decline also was greater in responders than in nonresponders (p = 0.009). Conclusions Patients with LAM may have partially reversible airflow obstruction. A positive response to bronchodilators is associated with an accelerated rate of decline in pulmonary function.
- Published
- 2009
19. Pneumothorax After Air Travel in Lymphangioleiomyomatosis, Idiopathic Pulmonary Fibrosis, and Sarcoidosis
- Author
-
Dara Burstein, Joseph R. Fontana, Nilo A. Avila, Joel Moss, Angelo M. Taveira-DaSilva, Olanda Hathaway, and Bernardette R. Gochuico
- Subjects
Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Pediatrics ,Aircraft ,Sarcoidosis ,Pulmonary Fibrosis ,Critical Care and Intensive Care Medicine ,Severity of Illness Index ,Idiopathic pulmonary fibrosis ,Pleural disease ,Risk Factors ,Pulmonary fibrosis ,Prevalence ,medicine ,Humans ,Lymphangioleiomyomatosis ,Analysis of Variance ,Lung ,business.industry ,Respiratory disease ,Pneumothorax ,Middle Aged ,respiratory system ,medicine.disease ,Respiratory Function Tests ,respiratory tract diseases ,Surgery ,surgical procedures, operative ,medicine.anatomical_structure ,Female ,Cardiology and Cardiovascular Medicine ,business ,human activities - Abstract
Background The prevalence of pneumothorax associated with travel in patients with interstitial lung diseases is unknown. In patients with lymphangioleiomyomatosis (LAM), in whom pneumothorax is common, patients are often concerned about the occurrence of a life-threatening event during air travel. The aim of this study was to determine the prevalence of pneumothorax associated with air travel in patients with LAM, idiopathic pulmonary fibrosis (IPF), and sarcoidosis. Methods Records and imaging studies of 449 patients traveling to the National Institutes of Health were reviewed. Results A total of 449 patients traveled 1,232 times; 299 by airplane (816 trips) and 150 by land (416 trips). Sixteen of 281 LAM patients arrived at their destination with a pneumothorax. In 5 patients, the diagnosis was made by chest roentgenogram, and in 11 patients by CT scans only. Of the 16 patients, 14 traveled by airplane and 2 by land. Seven of the 16 patients, 1 of whom traveled by train, had a new pneumothorax; 9 patients had chronic pneumothoraces. A new pneumothorax was more likely in patients with large cysts and more severe disease. The frequency of a new pneumothorax for LAM patients who traveled by airplane was 2.9% (1.1 per 100 flights) and by ground transportation, 1.3% (0.5 per 100 trips). No IPF (n = 76) or sarcoidosis (n = 92) patients presented with a pneumothorax. Conclusions In interstitial lung diseases with a high prevalence of spontaneous pneumothorax, there is a relatively low risk of pneumothorax following air travel. In LAM, the presence of a pneumothorax associated with air travel may be related to the high incidence of pneumothorax and not to travel itself.
- Published
- 2009
20. Serum Vascular Endothelial Growth Factor-D Levels in Patients With Lymphangioleiomyomatosis Reflect Lymphatic Involvement
- Author
-
Jing-Ping Lin, Connie G. Glasgow, Nilo A. Avila, Mario Stylianou, and Joel Moss
- Subjects
Male ,Pulmonary and Respiratory Medicine ,Pathology ,medicine.medical_specialty ,Angiomyolipoma ,Endothelium ,Vital Capacity ,Population ,Vascular Endothelial Growth Factor D ,Enzyme-Linked Immunosorbent Assay ,Critical Care and Intensive Care Medicine ,chemistry.chemical_compound ,immune system diseases ,Forced Expiratory Volume ,hemic and lymphatic diseases ,Humans ,Medicine ,Lymphangioleiomyomatosis ,education ,Lymphatic Vessels ,Original Research ,education.field_of_study ,Lung ,business.industry ,Respiratory disease ,Middle Aged ,bacterial infections and mycoses ,medicine.disease ,Vascular endothelial growth factor ,Logistic Models ,Phenotype ,medicine.anatomical_structure ,Lymphatic system ,chemistry ,Area Under Curve ,Female ,lipids (amino acids, peptides, and proteins) ,Cardiology and Cardiovascular Medicine ,business - Abstract
Lymphangioleiomyomatosis (LAM) is a rare multisystem disorder affecting primarily women of child-bearing age, and characterized by cystic lung destruction, tumors of the kidney (angiomyolipomas [AMLs]), and involvement of the axial lymphatics (lymphangioleiomyomas). Patients with LAM experience loss of pulmonary function attributed to the proliferation of abnormal-appearing smooth muscle-like cells (LAM cells). It is possible to group the LAM population by the presence or absence of extrapulmonary involvement (eg, AMLs, lymphangioleiomyomas, chylous effusions). Serum vascular endothelial growth factor (VEGF)-D, a lymphangiogenic factor, is higher in LAM patients than in healthy volunteers and has been proposed as a tool in the differential diagnosis of cystic lung disease. We assessed serum VEGF-D concentrations in relationship to clinical phenotype in LAM patients.Serum VEGF-D levels were quantified by enzyme immunosorbent assay for 111 patients with LAM and 40 healthy volunteers. VEGF-D levels in patients with pulmonary LAM, with or without extrapulmonary manifestations, were compared to those of healthy volunteers.Serum VEGF-D levels were greater in patients with LAM compared to those of healthy volunteers (p0.001). However, when patient samples were grouped based on the extent of lymphatic extrapulmonary involvement (eg, lymphangioleiomyomas and adenopathy), the statistical difference was maintained only for patients with LAM with lymphatic involvement (p0.001), not for those patients whose disease was restricted to the lung. Serum VEGF-D levels are a good biomarker for lymphatic involvement (area under the curve [AUC], 0.845; p0.0001), and a fair predictor for LAM disease (AUC, 0.751; p0.0001). Serum levels correlated to CT scan grade (p = 0.033).Serum VEGF-D concentration is a measure of lymphatic involvement in patients with LAM.
- Published
- 2009
21. Pulmonary Artery Pressure in Lymphangioleiomyomatosis
- Author
-
Angelo M. Taveira-DaSilva, Yukitaka Shizukuda, Joel Moss, Olanda Hathaway, Charles W. Birdsall, and Vandana Sachdev
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,business.industry ,VO2 max ,Physical exercise ,Critical Care and Intensive Care Medicine ,medicine.disease ,Pulmonary hypertension ,Hypoxemia ,Pulmonary function testing ,Surgery ,Blood pressure ,medicine.artery ,Internal medicine ,Pulmonary artery ,Lymphangioleiomyomatosis ,medicine ,Cardiology ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background Exercise-induced hypoxemia is frequent in patients with lymphangioleiomyomatosis (LAM) and could be associated with pulmonary hypertension. The aims of this study were to determine the prevalence of pulmonary hypertension in patients with LAM, to identify physiologic parameters associated with its occurrence, and to evaluate the effect of oxygen on response to exercise. Methods Studies were performed in 120 patients. Complete data, including exercise echocardiography, pulmonary function testing, and standard cardiopulmonary exercise testing, were obtained in 95 patients. Results Resting pulmonary artery pressure (PAP) was 26 ± 0.7 mm Hg (mean ± SEM). Eight patients had pulmonary hypertension (43 ± 3 mm Hg), and two patients had right ventricular dilatation. Ninety-five patients exercised (room air, n = 64; oxygen, n = 31) to a power of 58 ± 2 W (49% of predicted) and an estimated peak oxygen uptake of 938 ± 30 mL/min (56% of predicted). Sixty-one patients had a decline in arterial oxygen saturation (Sa o 2 ) > 3%, and 56 patients had an elevation in PAP > 40 mm Hg. Peak exercise PAP was negatively correlated with exercise Sa o 2 (p = 0.0005). Multivariate analysis showed that exercise Sa o 2 was the best predictor of exercise PAP (p = 0.012). Conclusions Although resting pulmonary hypertension is rare in patients with LAM, a rise in PAP at low exercise levels occurs frequently, in part related to exercise-induced hypoxemia. Optimization of oxygen administration during activities of daily living should be undertaken in patients with LAM to prevent hypoxemia and exercise-induced pulmonary hypertension.
- Published
- 2007
22. Incidence of Pneumothorax in Patients With Lymphangioleiomyomatosis Undergoing Pulmonary Function and Exercise Testing
- Author
-
Patricia Julien-Williams, Amanda M. Jones, Joel Moss, and Angelo M. Taveira-DaSilva
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,Male ,medicine.medical_specialty ,Critical Care and Intensive Care Medicine ,Risk Assessment ,Pulmonary function testing ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,In patient ,Selected Reports ,030212 general & internal medicine ,Lymphangioleiomyomatosis ,Intensive care medicine ,Lung ,Retrospective Studies ,business.industry ,Medical record ,Incidence (epidemiology) ,Incidence ,Pneumothorax ,respiratory system ,Middle Aged ,medicine.disease ,United States ,respiratory tract diseases ,Respiratory Function Tests ,Radiography ,Clinical research ,surgical procedures, operative ,030228 respiratory system ,Lung disease ,Exercise Test ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Because pneumothorax is frequent in lymphangioleiomyomatosis, patients have expressed concerns regarding the risk of pneumothorax associated with pulmonary function or exercise testing. Indeed, pneumothorax has been reported in patients with lung disease after both of these tests. The aim of this study was to determine the incidence of pneumothorax in patients with lymphangioleiomyomatosis during admissions to the National Institutes of Health Clinical Research Center between 1995 and 2015. Medical records were reviewed to identify patients who had a pneumothorax during their stay at the National Institutes of Health. A total of 691 patients underwent 4,523 pulmonary function tests and 1,900 exercise tests. Three patients developed pneumothorax after pulmonary function tests and/or exercise tests. The incidence of pneumothorax associated with lung function testing was 0.14 to 0.29 of 100 patients or 0.02 to 0.04 of 100 tests. The incidence of pneumothorax in patients undergoing exercise testing was 0.14 to 0.28 of 100 patients or 0.05 to 0.10 of 100 tests. The risk of pneumothorax associated with pulmonary function or exercise testing in patients with lymphangioleiomyomatosis is low.
- Published
- 2015
23. Genetics and Gene Expression in Lymphangioleiomyomatosis
- Author
-
Yi Zhang, Gustavo Pacheco-Rodriguez, Linda A. Stevens, Joel Moss, Denise M. Crooks, and Arnold S. Kristof
- Subjects
Pulmonary and Respiratory Medicine ,Pathology ,medicine.medical_specialty ,Lung ,business.industry ,medicine.medical_treatment ,Respiratory disease ,bacterial infections and mycoses ,Critical Care and Intensive Care Medicine ,medicine.disease ,Pathogenesis ,Tuberous sclerosis ,medicine.anatomical_structure ,immune system diseases ,hemic and lymphatic diseases ,Multifocal micronodular pneumocyte hyperplasia ,Lymphangioleiomyomatosis ,medicine ,Lung transplantation ,lipids (amino acids, peptides, and proteins) ,TSC2 ,Cardiology and Cardiovascular Medicine ,business - Abstract
Lymphangioleiomyomatosis (LAM) is a disease of unknown etiology that is characterized by the proliferation of abnormal smooth muscle cells (LAM cells) in the lung, which leads to cystic parenchymal destruction and progressive respiratory failure. Recent evidence suggests that the proliferative and invasive nature of LAM cells may be due, in part, to somatic mutations in the TSC2 gene, which has been implicated in the pathogenesis of tuberous sclerosis complex. Here, we describe the clinical and molecular characteristics of LAM, as well as the efforts now under way to understand the genetic and biochemical factors that lead to progressive pulmonary destruction and, ultimately, to lung transplantation or death.
- Published
- 2002
24. Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosis
- Author
-
Patricia Julien-Williams, Joel Moss, Amanda M. Jones, Angelo M. Taveira-DaSilva, and Mario Stylianou
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,Male ,medicine.medical_specialty ,Simvastatin ,Lung Neoplasms ,Pharmacology ,Critical Care and Intensive Care Medicine ,Gastroenterology ,Young Adult ,DLCO ,Internal medicine ,Diffusing capacity ,Forced Expiratory Volume ,medicine ,Humans ,cardiovascular diseases ,Lymphangioleiomyomatosis ,Adverse effect ,Retrospective Studies ,Original Research ,Sirolimus ,Leukopenia ,Dose-Response Relationship, Drug ,business.industry ,Therapeutic effect ,Middle Aged ,equipment and supplies ,medicine.disease ,Respiratory Function Tests ,surgical procedures, operative ,Treatment Outcome ,cardiovascular system ,lipids (amino acids, peptides, and proteins) ,Drug Therapy, Combination ,Female ,medicine.symptom ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Cardiology and Cardiovascular Medicine ,business ,Immunosuppressive Agents ,medicine.drug ,Follow-Up Studies - Abstract
BACKGROUND Combined simvastatin and sirolimus therapy reduces tuberous sclerosis complex 2-null lesions and alveolar destruction in a mouse model of lymphangioleiomyomatosis (LAM), suggesting that therapy with both drugs may benefit patients with LAM. METHODS To determine whether simvastatin changed the prevalence of adverse events or altered the therapeutic effects of sirolimus, we recorded adverse events and changes in lung function in patients with LAM treated with simvastatin plus sirolimus (n = 14), sirolimus alone (n = 44), or simvastatin alone (n = 20). RESULTS Sirolimus-related adverse events in the simvastatin plus sirolimus and sirolimus-only groups were 64% and 66% for stomatitis, 50% and 52% for diarrhea, 50% and 45% for peripheral edema, 36% and 61% for acne, 36% and 30% for hypertension, 29% and 27% for proteinuria, 29% and 27% for leukopenia, and 21% and 27% for hypercholesterolemia. The frequency of simvastatin-related adverse events in the simvastatin-only and simvastatin plus sirolimus groups were 60% and 50% for arthralgias and 35% and 36% for myopathy. Before simvastatin plus sirolimus therapy, FEV 1 and diffusing capacity of the lung for carbon monoxide (Dlco) yearly rates of change were, respectively, −1.4 ± 0.2 and −1.8 ± 0.2% predicted. After simvastatin plus sirolimus therapy, these rates changed to +1.2 ± 0.5 ( P = .635) and +0.3 ± 0.4% predicted ( P = .412), respectively. In 44 patients treated with sirolimus alone, FEV 1 and Dlco rates of change were −1.7 ± 0.1 and −2.2 ± 0.1% predicted before treatment and +1.7 ± 0.3 and +0.7 ± 0.3% predicted after treatment ( P CONCLUSIONS Therapy with sirolimus and simvastatin does not increase the prevalence of drug adverse events or alter the therapeutic effects of sirolimus.
- Published
- 2014
25. Comprehensive Evaluation of 35 Patients With Lymphangioleiomyomatosis
- Author
-
Koji Horiba, William D. Travis, Victor J. Ferrans, Nilo A. Avila, Joel Moss, Shan C. Chu, Clara C. Chen, and Jiro Usuki
- Subjects
Adult ,Radiography, Abdominal ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Angiomyolipoma ,Adolescent ,Lung biopsy ,Critical Care and Intensive Care Medicine ,Ventilation/perfusion ratio ,Pulmonary function testing ,Diffusing capacity ,Abdomen ,medicine ,Humans ,Lymphangioleiomyomatosis ,Prospective Studies ,Radionuclide Imaging ,Lung ,Ultrasonography ,business.industry ,Middle Aged ,medicine.disease ,Immunohistochemistry ,respiratory tract diseases ,medicine.anatomical_structure ,Pneumothorax ,Respiratory Mechanics ,Female ,Radiology ,Tomography, X-Ray Computed ,Cardiology and Cardiovascular Medicine ,business ,Bronchoalveolar Lavage Fluid - Abstract
Objectives To evaluate comprehensively the characteristics of lymphangioleiomyomatosis (LAM), with emphasis on the application of imaging and immunohistochemical methods. Design Prospective study. Patients Thirty-five female subjects with LAM. Setting Clinical Center, National Institutes of Health. Interventions BAL, pulmonary function test, ventilation/perfusion lung scans, CT of the chest and abdomen, ultrasonography of abdomen, and immunohistochemical study of lung biopsy specimens. Results Most patients had exertional dyspnea (83%) and pneumothorax (69%). BAL did not show diagnostic changes. The most common abnormalities on pulmonary function tests were decreased diffusing capacity of carbon monoxide (83%), hypoxemia (57%), and airway obstruction (51%). Bronchodilator response was found in 26% of patients. CT, which is almost pathognomonic, showed numerous thin-walled cysts throughout both lungs in all patients. Thirty-four patients (97%) had abnormal ventilation and/or perfusion lung scans. An unusual "speckling" pattern was observed on ventilation scans of 74% of patients. Common extrapulmonary features were retroperitoneal adenopathy (77%) and renal angiomyolipomas (60%). The percentage of abnormal smooth muscle cells (LAM cells), reactive with HMB45, varied from 17 to 67% in 10 lung biopsy specimens. Conclusions Improved diagnostic methods have defined the abnormalities in patients with pulmonary LAM and increased the potential for early recognition and treatment of this disorder. Patients with LAM should be evaluated for bronchodilator responsiveness and may benefit from a trial of bronchodilators.
- Published
- 1999
26. Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis
- Author
-
Sergio, Harari, Roberto, Cassandro, Iacopo, Chiodini, Jacopo, Chiodini, Angelo M, Taveira-DaSilva, and Joel, Moss
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,Male ,medicine.medical_specialty ,Bone density ,Antineoplastic Agents, Hormonal ,Functional Residual Capacity ,medicine.medical_treatment ,Osteoporosis ,Vital Capacity ,Estrogen receptor ,Physiology ,Critical Care and Intensive Care Medicine ,Article ,Pulmonary function testing ,Bone Density ,Internal medicine ,Forced Expiratory Volume ,medicine ,Lung transplantation ,Humans ,Lymphangioleiomyomatosis ,Lung ,Triptorelin Pamoate ,business.industry ,Middle Aged ,Antiestrogen ,medicine.disease ,Triptorelin ,Endocrinology ,Premenopause ,Female ,Cardiology and Cardiovascular Medicine ,business ,Tomography, X-Ray Computed ,medicine.drug - Abstract
Background Lymphangioleiomyomatosis (LAM), a multisystem disease occurring primarily in women, is characterized by cystic lung destruction, and kidney and lymphatic tumors, caused by the proliferation of abnormal-appearing cells ( ie , LAM cells) with a smooth muscle cell phenotype that express melanoma antigens and are capable of metastasizing. Estrogen receptors are present in LAM cells, and this finding, along with reports of disease progression during pregnancy or following exogenous estrogen administration, suggest the involvement of estrogens in the pathogenesis of LAM. Consequently, antiestrogen therapies have been employed in treatment. The goal of this prospective study was to evaluate the efficacy of triptorelin, a gonadotrophin-releasing hormone analogue, in 11 premenopausal women with LAM. Methods Patients were evaluated at baseline and every 3 to 6 months thereafter, for a total of 36 months. Hormonal assays, pulmonary function tests, 6-min walk tests, high-resolution CT scans of the chest, and bone mineral density studies were performed. Results Gonadal suppression was achieved in all patients. Overall, a significant decline in lung function was observed; two patients underwent lung transplantation 1 year after study enrollment, and another patient was lost to follow-up. Treatment with triptorelin was associated with a decline in bone mineral density. Conclusions Triptorelin appears not to prevent a decline in lung function in patients with LAM. Its use, however, may be associated with the loss of bone mineral density.
- Published
- 2007
27. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone
- Author
-
Angelo M. Taveira-DaSilva, Joel Moss, Carolyn J. Hedin, Mario Stylianou, and Olanda Hathaway
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,medicine.medical_specialty ,Critical Care and Intensive Care Medicine ,Gastroenterology ,Pulmonary function testing ,DLCO ,Internal medicine ,Forced Expiratory Volume ,medicine ,Humans ,Respiratory function ,Lymphangioleiomyomatosis ,Lung ,Progesterone ,Aged ,business.industry ,Respiratory disease ,respiratory system ,Middle Aged ,medicine.disease ,Respiratory Function Tests ,Endocrinology ,medicine.anatomical_structure ,Respiratory failure ,Population study ,Pulmonary Diffusing Capacity ,Female ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies - Abstract
Study objective: Lymphangioleiomyomatosis (LAM), a disease affecting women and causing cystic lung lesions, and, in some instances, leading to respiratory failure and death, appears to be exacerbated by estrogens. Hence, hormonal therapy with progesterone is frequently employed; however, efficacy has not been demonstrated. Our aim was to determine whether progesterone administration slowed the decline in lung function in LAM. Design: Retrospective study. Setting: National Institutes of Health, Bethesda, MD. Design and subjects: The study population comprised 348 patients with LAM participating in a longitudinal research protocol. Declines in diffusion capacity of the lung for carbon monoxide (Dlco) and FEV 1 were measured in 275 patients observed for approximately 4 years. The declines in Dlco and FEV 1 of patients treated with progesterone, po (n = 67) or IM (n = 72), were compared with those of untreated patients (n = 136). Measurements and results: Overall yearly rates of decline in Dlco and FEV 1 were 2.4 ≤ 0.4% predicted (0.69 ≤ 0.07 mL/min/mm Hg) and 1.7 ≤ 0.4% predicted (75 ≤ 9 mL), respectively (mean ≤ SEM). The most significant predictors of functional decline were initial lung function and age. After adjusting for initial FEV 1 , age, and duration of disease, patients treated with IM progesterone tended to have lower rates of decline in FEV 1 than patients treated po (1.9 ≤ 0.6% predicted vs 3.2 ≤ 0.8% predicted, respectively; p=0.081). However, there was no significant difference in rates of decline in FEV 1 between patients treated with IM progesterone and untreated patients (1.9 ≤ 0.6% predicted vs 0.8 ≤ 0.5% predicted, respectively; p=0.520), and patients treated with po progesterone and untreated patients (3.2 ≤ 0.8% predicted vs 0.8 ≤ 0.5% predicted, respectively; p=0.064). After adjusting for initial Dlco, rates of decline in Dlco were significantly higher in patients treated with po progesterone (3.6 ≤ 0.7% predicted, p=0.002) and IM progesterone (2.8 ≤ 0.5% predicted, p=0.022) than in untreated patients (1.6 ≤ 0.6% predicted). Conclusions: Within the limitations of a retrospective study, our data suggest that progesterone therapy does not slow the decline in lung function in LAM.
- Published
- 2004
28. Ahead of the Curve
- Author
-
Joel Moss
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,business.industry ,medicine ,Medical emergency ,Cardiology and Cardiovascular Medicine ,Critical Care and Intensive Care Medicine ,Intensive care medicine ,medicine.disease ,business ,Asthma - Published
- 2011
29. ROLE OF LUNG TRANSPLANTATION IN THE MANAGEMENT OF PATIENTS WITH LAM: BASELINE DATA FROM THE NIH LAM REGISTRY
- Author
-
Gerald J. Beck, Joel Moss, Jar-Chi Lee, Jay H. Ryu, Kevin K. Brown, and Janet R. Maurer
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,business.industry ,Internal medicine ,medicine.medical_treatment ,medicine ,Lung transplantation ,Baseline data ,Cardiology and Cardiovascular Medicine ,Critical Care and Intensive Care Medicine ,Intensive care medicine ,business - Published
- 2005
30. Fibroblasts: Important Producers and Targets of inflammatory Prostaglandins in the Lungs
- Author
-
B. Hom, J. Oberpriller, L Stier, Ronald G. Crystal, Joel Moss, Toshio Ozaki, and Stephen I. Rennard
- Subjects
Pulmonary and Respiratory Medicine ,Lung ,business.industry ,Prostaglandins E ,Fibroblasts ,Bradykinin ,Critical Care and Intensive Care Medicine ,Dinoprostone ,Fibronectins ,Fetus ,medicine.anatomical_structure ,Immunology ,medicine ,Humans ,Collagen ,Cardiology and Cardiovascular Medicine ,Fibroblast ,business ,Cells, Cultured - Published
- 1983
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.